We are live on ! Find out more
FCMI

Foresite Capital Management IV Portfolio holdings

AUM $237M
1-Year Est. Return 107.53%
This Fund
S&P 500
This Quarter Est. Return
+6.79%
1 Year Est. Return
+107.53%
3 Year Est. Return
+149.4%
5 Year Est. Return
+13.8%
10 Year Est. Return
–
AUM
$180M
AUM Growth
-$23.4M
Cap. Flow
-$2.17M
Cap. Flow %
-1.21%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
LYEL icon
Lyell Immunopharma
LYEL
+$2.17M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHVS icon
1
Pharvaris
PHVS
$2.28B
$78.1M 43.39%
3,743,450
– –
CBAY
2
DELISTED
Cymabay Therapeutics
CBAY
$26.6M 14.8%
1,787,094
– –
ACRS icon
3
Aclaris Therapeutics
ACRS
$726M
$19.2M 10.68%
2,808,034
– –
KURA icon
4
Kura Oncology
KURA
$800M
$16.9M 9.37%
1,849,947
– –
KNTE
5
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$13.5M 7.52%
9,671,643
– –
LYEL icon
6
Lyell Immunopharma
LYEL
$317M
$12.9M 7.17%
439,241
-45,759
-9% -$2.17M
SNDX icon
7
Syndax Pharmaceuticals
SNDX
$1.69B
$12.7M 7.06%
875,000
– –

Similar funds

BCM
Birmingham Capital Management Birmingham, Alabama $237M AUM 32.7% 1-Year Est. Return
AG
ASO Group Road Town $237M AUM
FL
FreeGulliver LLC New Orleans, Louisiana $237M AUM 21.92% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
MFA
Millington Financial Advisors Naperville, Illinois $237M AUM 22.22% 1-Year Est. Return
TCM
Tekne Capital Management New York $237M AUM 62.98% 1-Year Est. Return
WW
Windle Wealth Oklahoma City, Oklahoma $237M AUM 22.79% 1-Year Est. Return
CB
CNB Bank Clearfield, Pennsylvania $238M AUM 26.55% 1-Year Est. Return

Foresite Capital Management IV's Q3 2023 Portfolio in Review

As of Q3 2023, Foresite Capital Management IV held 7 positions worth $180M, down 11% from $203M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q3 2023: portfolio turnover was 0%. Foresite Capital Management IV opened no new positions and made no exits, leaving the 7-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Foresite Capital Management IV's biggest Q3 2023 reduction was Lyell Immunopharma, cutting an estimated $2.17M.
  • Foresite Capital Management IV's ten largest holdings make up 100% of its $180M portfolio in Q3 2023.
  • Foresite Capital Management IV opened 0 new positions and closed 0 in Q3 2023.
  • Foresite Capital Management IV's portfolio value fell 11% quarter-over-quarter to $180M.

Based on Foresite Capital Management IV's 13F filing for Q3 2023, filed 13 Nov 2023.